Litcius/Paper detail

Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial

Feng Xue, Huiyuan Li, Xia Wu, Wei Liu, Feixu Zhang, Dingyue Tang, Yunfei Chen, Wentian Wang, Ying Chi, Jing Zheng, Zengmin Du, Wei Jiang, Chen Zhong, Jun Wei, Ping Zhu, Rongfeng Fu, Xiao Fan Liu, Ling‐Ling Chen, Xiaolei Pei, Junjiang Sun, Tao Cheng, Renchi Yang, Xiao Xiao, Lei Zhang

2022The Lancet Haematology79 citationsDOI

Topics & Concepts

MedicineFactor IXAdverse effectHaemophilia BInternal medicineHaemophiliaHematologyIncidence (geometry)GastroenterologySurgeryHaemophilia AOpticsPhysicsHemophilia Treatment and ResearchVirus-based gene therapy researchNeurogenetic and Muscular Disorders Research
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial | Litcius